Structure‐Guided Optimization of 1,2,4‐Triazole‐Thione‐Based Mannich Derivatives as Dual‐Target Modulators: AChE / MAO ‐B
Chemical Biology & Drug Design · 2026-07 · 108 (1)
DOI: 10.1111/cbdd.70347 ↗At a glance
Journal article in Chemical Biology & Drug Design, published online on 2026-07-14. Written by Hasan Erdinç Sellitepe and 6 co-authors. Institution: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Karadeniz Technical University, Trabzon, Türkiye. Major MEDLINE topics: Triazoles, Acetylcholinesterase, Cholinesterase Inhibitors, Monoamine Oxidase. 43 references. The full text is freely available in PubMed Central.
Abstract (original language)
Diseases such as Alzheimer's, Parkinson's, and depression result from neurotransmitter imbalances. In particular, for AD, it is critical to inhibit AChE to preserve the decline in acetylcholine levels and to block excessive MAO‐B activity, which leads to nerve damage and cognitive impairment. As current scientific research has moved away from the “one drug for one target” approach toward a “multi‐target” strategy, dual‐acting inhibitors that simultaneously inhibit both AChE and MAO‐B enzymes are considered the most promising new drug candidates for the treatment of Alzheimer's disease. In this study, we investigated the inhibition of AChE, BChE, MAO‐A, and MAO‐B in the pathophysiology of AD as a working group. Within the scope, 10 new compounds ( 5a – j ) were synthesized, consisting of a phenolic ring, a secondary or tertiary amine tail, and a 1,2,4‐triazole core. The cholinesterase and MAO inhibitory profiles of the compounds were investigated using both in vitro and in silico methods. Compound 5b exhibited dual inhibitory activity against AChE and MAO‐B enzymes, with IC 50 values of 0.136 ± 0.006 μM and 0.108 ± 0.005 μM, respectively. In accordance with 5b , it interacted with crucial amino acids of the h AChE and h MAO‐B enzymes in the docking studies. These results suggest that 5b is a dual‐target inhibitor of AChE and MAO‐B and represents a promising therapeutic option for the treatment of Alzheimer's disease.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Karadeniz Technical University, Trabzon, Türkiye.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Türkiye.
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Karadeniz Technical University, Trabzon, Türkiye.
ORCID profiles: Hasan Erdinç Sellitepe, Ahmet Buğra Aksel, Hilal Zıvalı, Ezgi Pehlivanlar Yavrucu, Begüm Nurpelin Sağlık Özkan, İnci Selin Doğan, Kutsal Özcan Kosif
Cite
APA
Sellitepe, H. E., Aksel, A. B., Zıvalı, H., Pehlivanlar Yavrucu, E., Sağlık Özkan, B. N., Doğan, İ. S., & Özcan Kosif, K. (2026). Structure‐Guided Optimization of 1,2,4‐Triazole‐Thione‐Based Mannich Derivatives as Dual‐Target Modulators: AChE / MAO ‐B. Chemical Biology & Drug Design, 108(1). https://doi.org/10.1111/cbdd.70347
Vancouver
Sellitepe HE, Aksel AB, Zıvalı H, Pehlivanlar Yavrucu E, Sağlık Özkan BN, Doğan İS, et al. Structure‐Guided Optimization of 1,2,4‐Triazole‐Thione‐Based Mannich Derivatives as Dual‐Target Modulators: AChE / MAO ‐B. Chemical Biology & Drug Design. 2026;108(1). doi:10.1111/cbdd.70347
BibTeX
@article{Sellitepe2026,
author = {Sellitepe, Hasan Erdinç and Aksel, Ahmet Buğra and Zıvalı, Hilal and Pehlivanlar Yavrucu, Ezgi and Sağlık Özkan, Begüm Nurpelin and Doğan, İnci Selin and Özcan Kosif, Kutsal},
title = {Structure‐Guided Optimization of 1,2,4‐Triazole‐Thione‐Based Mannich Derivatives as Dual‐Target Modulators: AChE / MAO ‐B},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {108},
number = {1},
doi = {10.1111/cbdd.70347}
}
EUVIMED